European Commission Approves Micardis Of Boehringer
Boehringer Ingelheim has reported that the European Commission has approved Micardis (telmisartan) for the reduction of cardiovascular morbidity in patients with manifest atherothrombotic cardiovascular disease or type 2
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.